Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
“We are delighted to receive a Locilex patent in Japan, the third largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement.
“We anticipate the issuance of additional Locilex patents in other major international markets, which will allow us to continue to establish commercial viability of Locilex throughout the world,” he added.
Locilex, which is in Phase 3 testing, is targeted for treatment of mild infections of diabetic foot ulcers.
Based on a compilation of available clinical and microbiology data, Locilex is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).
